Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.
Mathias Castonguay, Mary Ann Anderson, Philip Thompson...
https://pubmed.ncbi.nlm.nih.gov/41843779/Actively Recruiting
Led by AstraZeneca · Updated on 2026-10-23
80
Participants Needed
47
Research Sites
203 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of a limited duration treatment combining acalabrutinib and venetoclax in patients with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have relapsed after initially responding to first-line therapy with covalent BTKi and BCL2i drugs, with or without obinutuzumab. The study focuses on participants who maintained at least a partial remission for two years following their first treatment. Participants will receive a lead-in phase of two cycles of acalabrutinib, followed by either 12 or 22 cycles of the combined acalabrutinib and venetoclax treatment, depending on assigned risk cohort based on disease markers IGHV mutation and TP53 status. The total study duration for each participant is approximately five years, which includes up to four years of follow-up after treatment completion. During the study, participants will undergo regular assessments to measure the overall response rate at multiple time points during treatment cycles and annually thereafter. Additional evaluations include progression-free survival, duration of response, event-free survival, time to next treatment, overall survival, and rates of undetectable minimal residual disease. Safety and tolerability of the second-line treatment will be monitored throughout the five-year period. Participants will have visits and tests according to this schedule to track treatment effects and disease status.
CONDITIONS
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
A
AstraZeneca Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
AbbVie
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | MAVRiC regimen | Fixed‑duration venetoclax retreatment |
|---|---|---|
| What it is | An experimental single‑arm regimen of acalabrutinib plus venetoclax, given for a fixed duration based on mutation‑guided risk (14 or 24 cycles depending on genetic risk) | Retreatment with fixed‑duration venetoclax‑based combinations (often with anti‑CD20 or BTKi) is used in relapsed/refractory CLL/SLL |
| Role in trial | Investigational treatment being studied for second‑line use | Represents an external current‑practice retreatment strategy not evaluated within this trial |
| Primary use | To induce response in relapsed CLL/SLL patients after prior BTKi+BCL2i therapy | Used to induce responses in CLL/SLL patients relapsing after prior targeted therapy |
| How it is given or performed | Administered orally in 28‑day cycles, number of cycles determined by risk genetics (mutation‑guided) | Venetoclax given in fixed‑duration regimens (e.g. 12‑24 months), often with anti‑CD20 or BTKi |
| Evidence status | Efficacy under investigation; no published results yet | Retreatment yields high response rates and prolonged remissions (ORR ~72‑100%, PFS ~23‑58 months) |
| Important risks | Safety profile to be determined; trial will monitor adverse events over 5 years | Known risks include tumor lysis and cytopenias from venetoclax regimens |
| Important limitations | Single‑arm study without randomized control limits comparative efficacy interpretation | Retreatment data derive from heterogeneous small studies and may not match trial‑eligible population exactly |
| Patient impact | Not yet established; outcomes dependent on trial results | High response rates and durable remissions suggest meaningful benefit to patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 14 to 24 cycles (each cycle is 28 days)
Participants receive two cycles of acalabrutinib alone followed by combined acalabrutinib and venetoclax treatment. The number of combined treatment cycles depends on the participant's risk group.
Regular visits during treatment cycles
Duration - 3 to 4 years
Participants are monitored for up to 4 years after treatment to assess long-term outcomes and safety.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Mathias Castonguay, Mary Ann Anderson, Philip Thompson...
https://pubmed.ncbi.nlm.nih.gov/41843779/AstraZeneca
Lead Sponsor
AbbVie
Collaborating Sponsor